• Profile
Close

Early sedation with dexmedetomidine in critically ill patients

New England Journal of Medicine May 24, 2019

Shehabi Y, et al. - Researchers conducted this open-label, randomized trial to further study the use of dexmedetomidine as the sole or primary sedative agent in patients undergoing mechanical ventilation. They recruited critically ill adults who had undergone intensive care unit (ICU) ventilation for < 12 hours and were expected to continue receiving dexmedetomidine as a single or primary sedative or usual care (propofol, midazolam, or other sedatives) for longer than the next calendar day. A total of 4,000 patients were included in the study. Among patients undergoing mechanical ventilation at the ICU, patients receiving early dexmedetomidine for sedation had a 90-day death rate similar to that in the usual-care group, and required additional sedatives to achieve the prescribed sedation level. In the dexmedetomidine group, more adverse events were reported than in the usual-care group. In the dexmedetomidine group, bradycardia and hypotension were more common.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay